Neophobia, NQO1 and SIRT1 as premorbid and prodromal indicators of AD in 3xTg-AD mice

Behavioural Brain Research

Volumn 271, Issue , 2014, Pages 140-146

  Torres Lista, Virginia ^a   Parrado Fernández, Cristina ^b   Alvarez Montón, Ismael ^a   Frontiñán Rubio, Javier ^b   Durán Prado, Mario ^b   Peinado, Juan Ramón ^b   Johansson, Björn ^c   Alcaín, Francisco Javier ^b   Giménez Llort, Lydia ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

3xTg AD mouse; AD C; AD P; Alzheimer's disease; Antioxidant enzymes; Behavior

Indexed keywords

AMYLOID BETA PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; ENZYME; NAD(P)H:QUINONE OXIDOREDUCTASE 1; SIRTUIN 1; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SIRT1 PROTEIN, HUMAN; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEFENSE MECHANISM; DOWN REGULATION; EMOTIONAL STRESS; EMOTIONALITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HIPPOCAMPUS; IMMUNOREACTIVITY; MALE; MOUSE; NEOPHOBIA; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROTEIN EXPRESSION; REARING; AGING; ANIMAL; C57BL MOUSE; DISEASE MODEL; METABOLISM; PSYCHOLOGY; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRAL CORTEX; COGNITION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NAD(P)H DEHYDROGENASE (QUINONE); SIRTUIN 1; SUPEROXIDE DISMUTASE;

EID: 84902690102     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.04.055     Document Type: Article

References (27)

1. Sperling R.A., Karlawish J., Johnson K.A. Preclinical Alzheimer disease - the challenges ahead. Nat Rev Neurol 2013, 9(January):54-58. 10.1038/nrneurol.2012.241.
2. Bailey P. Biological markers of Alzheimer's disease. Can J Neurol Sci 2007, 34(Suppl. 1):S72-S76.
3. Lladó A., Sánchez-Valle R. Focusing on atypical symptoms for improved diagnosis of early-onset Alzheimer's disease. Future Neurol 2011, 6:575-578.
4. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimer's Dement 2007, 3:186-191.
5. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular AB and synaptic dysfunction. Neuron 2003, 39:409-421.
6. Giménez-Llort L., Torres-Lista V., De la Fuente M. Crosstalk between the nervous and the immune system during the prodromal stages of Alzheimer's disease. Curr Pharm Des 2014, in press and Epub ahead of print. 10.2174/1381612820666140130205500.
7. Giménez-Llort L., Blázquez G., Cañete T., Rosa R., Vivo M., Oddo S., et al. Modeling neuropsychiatric symptoms of Alzheimer's disease dementia in 3xTg-AD mice. Alzheimer's disease: new advances 2006, 513-516. Medimond, Englewood, NJ, USA. K. Iqbal, B. Winblad, J. Avila (Eds.).
8. Giménez-Llort L., Garcia Y., Buccieri K., Revilla S., Sunol C., Cristofol R., et al. Gender-specific neuroimmunoendocrine response to treadmill exercise in 3xTg-AD mice. Int J Alzheimers Dis 2010, 128354.
9. Gulinello M., Gertner M., Mendoza G., Schoenfeld B.P., Oddo S., LaFerla F.M., et al. Validation of a 2-day water maze protocol in mice. Behav Brain Res 2009, 196:220-227.
10. García-Mesa Y., Lopez-Ramos J.C., Gimenez-Llort L., Revilla S., Guerra R., Gruart A., et al. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice. J Alzheimers Dis 2011, 24(3):421-454.
11. España J., Giménez-Llort L., Valero J., Miñano A., Rábano A., Rodríguez-Álvarez J., et al. Intraneuronal b-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry 2010, 67:513-521.
12. Giuliani D., Ottani A., Zaffe D., Galantucci M., Strinati F., Lodi R., et al. Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms. Neurobiol Learn Mem 2013, 104:82-91.
13. Giuliani D., Bitto A., Galantucci M., Zaffe D., Ottani A., Irrera N., et al. Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways. Neurobiol Aging 2014, 35:537-547.
14. Resende R., Moreira P.I., Proença T., Deshpande A., Busciglio J., Pereira C., et al. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer's disease. Free Rad Biol Med 2008, 44:2051-2057.
15. SantaCruz K.S., Yazlovitskaya E., Collins J., Johnson J., DeCarli C. Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease. Neurobiol Aging 2004, 25:63-69.
16. Murakami K., Murata N., Noda Y., Tahara S., Kaneko T., Kinoshita N., et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 2011, 286:44557-44568.
17. Revilla S., Suñol C., García-Mesa Y., Giménez-Llort L., Sanfeliu C., Cristòfol R. Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. Neuropharmacology 2014, 81:55-63.
18. Julien C., Tremblay C., Émond V., Lebbadi M., Salem M., Bennett D.A., et al. SIRT1 decrease parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 2009, 68:48-58.
19. Cimini A., Moreno S., D'Amelio M., Cristiano L., D'Angelo B., Falone S., et al. Early biochemical and morphological modifications in the brain of a transgenic mouse model of Alzheimer's disease: a role for peroxisomes. J Alzheimers Dis 2009, 18:935-952.
20. Marques S.C.F., Lemos R., Ferreiro E., Martins E.M., De Medoça A., Santana I., et al. Epigenetic regulation of BACE 1 in Alzheimer's disease patients and in transgenic mice. Neuroscience 2012, 220:256-266.
21. Venkateshappa C., Harish G., Mahadevan A., Srinivas Bharath M.M., Shankar S.K. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: implications for neurodegeneration in Alzheimer's disease. Neurochem Res 2012, 37:1601-1614.
22. Alcain F.J., Villalba J.M. NQO1 antitumor directed drugs. Expert Opin Ther Patents 2007, 17:1-17.
23. Bello R.I., Kagan V.E., Tyurin V., Navarro F., Alcain F.J., Villalba J.M. Regeneration of lipophilic antioxidants by NAD(P)H:quinone oxidoreductase 1. Protoplasma 2003, 221:129-135.
24. Nishida Y., Yokota T., Takahashi T., Uchihara T., Jishage K-i., Mizusawa H. Deletion of vitamin E enhances phenotype of Alzheimer disease model mouse. Biochem Biophys Res Commun 2006, 350:530-536.
25. Siegel D., Gustafson D.L., Dehn D.L., Han J.Y., Boonchoong P., Berliner L.J., et al. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004, 65:1238-1247.
26. Tsvetkov P., Adamovich Y., Elliott E., Shaul Y. E3 ligase STUB1/CHIP regulates NAD(P)H:quinone oxidoreductase 1 (NQO1) accumulation in aged brain, a process impaired in certain Alzheimer disease patients. J Biol Chem 2011, 286:8839-8845.
27. Kanninen K., Malm T.M., Jyrkkänen H.-K., Goldsteins G., Keksa-Goldsteine V., Tanila H., et al. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cel Neurosci 2008, 39:302-313.